Research programme: chikungunya vaccine - Takeda/Zydus Cadila

Drug Profile

Research programme: chikungunya vaccine - Takeda/Zydus Cadila

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda; Zydus Cadila
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Chikungunya virus infections

Most Recent Events

  • 20 Sep 2016 Early research in Chikungunya virus infections in India (unspecified route)
  • 20 Sep 2016 Takeda and Zydus Cadila agree to co-develop Chikungunya vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top